|
related topics |
{product, candidate, development} |
{stock, price, share} |
{interest, director, officer} |
{control, financial, internal} |
{property, intellectual, protect} |
{product, market, service} |
{stock, price, operating} |
{cost, contract, operation} |
{regulation, change, law} |
{personnel, key, retain} |
{regulation, government, change} |
|
An investment in our Common Stock is highly speculative, involves a high degree of risk and should be considered only by those persons who are able to afford a loss of their entire investment. In evaluating the Company and our business, prospective investors should carefully consider the following risk factors in addition to the other information included in this Annual Report.
We have a history of losses and may incur losses in the future.
Technology advances may make our technology obsolete or less competitive
Our products and services operate in a heavily regulated environment where new regulations may cause use to incur losses
Our technologies face uncertain market value.
We are deploying new and unproven technologies, which make evaluation of our business and prospects difficult, and we may be forced to cease operations if we do not develop commercially successful products.
If we do not enter into successful partnerships and collaborations with other companies, we may not be able to fully develop our technologies or products, and our business would be harmed.
We have limited experience commercially manufacturing, marketing or selling any of our potential products and services, and unless we develop or acquire these capabilities, we may not be successful.
Our future success depends on the continued service of our engineering, technical and key management personnel and our ability to identify, hire and retain additional engineering, technical and key management personnel.
Any inability to adequately protect our proprietary technologies could materially harm our competitive position and financial results.
We intend to operate in international markets the complexities of which may exceed our ability to anticipate and prepare for differences in regulations, operations and financial management
As a public company we are subject to complex legal and accounting requirements that will require us to incur significant expenses and will expose us to risk of non-compliance.
Future sales or the potential for future sales of our securities may cause the trading price of our common stock to decline and could impair our ability to raise capital through subsequent equity offerings.
We may fail to meet market expectations because of fluctuations in our quarterly operating results, which could cause our stock price to decline.
Our Common Stock Is Subject To Penny Stock Regulation
We Do Not Intend To Pay Dividends
Failure To Achieve And Maintain Effective Internal Controls In Accordance With Section 404 Of The Sarbanes-Oxley Act Could Have A Material Adverse Effect On Our Business And Operating Results.
The Report of Our Independent Registered Public Accounting Firm Contains Explanatory Language That Substantial Doubt Exists About Our Ability To Continue As A Going Concern
Full 10-K form ▸
|
|
related documents |
1298700--11/17/2008--Verdant_Technology_CORP |
849636--4/8/2010--CORTEX_PHARMACEUTICALS_INC/DE/ |
838879--4/15/2010--RADIENT_PHARMACEUTICALS_Corp |
1072379--4/17/2007--NORTHWEST_BIOTHERAPEUTICS_INC |
1072379--4/18/2006--NORTHWEST_BIOTHERAPEUTICS_INC |
1017491--3/26/2007--NEXMED_INC |
849636--4/15/2009--CORTEX_PHARMACEUTICALS_INC/DE/ |
849636--3/15/2007--CORTEX_PHARMACEUTICALS_INC/DE/ |
849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
891288--3/18/2008--QUESTCOR_PHARMACEUTICALS_INC |
849636--3/17/2008--CORTEX_PHARMACEUTICALS_INC/DE/ |
1030839--2/13/2007--Synovics_Pharmaceuticals |
71478--3/28/2008--LIPID_SCIENCES_INC/ |
1041024--3/24/2008--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA |
71478--3/15/2006--LIPID_SCIENCES_INC/ |
1016546--3/13/2007--ALTAIR_NANOTECHNOLOGIES_INC |
1041024--3/16/2009--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
1364544--4/2/2009--Craft_College_Inc |
1017491--3/16/2006--NEXMED_INC |
1041024--3/12/2010--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
867840--9/26/2008--PRECISION_OPTICS_CORPORATION_INC |
1096560--4/2/2007--SULPHCO_INC |
1325279--4/15/2010--CELLCYTE_GENETICS_CORP |
1436083--7/20/2009--New_Millennium_Products |
1398702--3/29/2010--TECKMINE_INDUSTRIES_INC. |
922330--7/30/2010--REGI_U_S_INC |
838879--3/31/2008--AMDL_INC |
867840--9/21/2010--PRECISION_OPTICS_CORPORATION_INC |
867840--9/28/2009--PRECISION_OPTICS_CORPORATION_INC |
|